Buttercup

Quick links to important sections

Buttercup

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buttercup

Quick Facts

Property Description
Active Ingredient Hexylresorcinol (INN)
Form Oromucosal Lozenge (most common)
Pharmacological Class Local Anesthetic and Topical Anti-infective
Common Use Symptomatic relief of minor sore throat and mouth irritation
Origin Synthetic organic compound (Phenol derivative)

What Type of Medicine is Buttercup and What is its Primary Class?

Buttercup is an Over-The-Counter (OTC) medicinal product containing Hexylresorcinol, a compound known for its dual functionality. The drug is classified as a Local Anesthetic and a Topical Anti-infective, positioning it within the therapeutic category of Mouth and Throat Products for the self-management of minor discomfort. This classification is utilized to provide symptomatic relief. The dual action profile is a key distinguishing feature of this preparation compared to single-agent formulations, allowing it to address both the sensation of pain and surface microbial load simultaneously.

Hexylresorcinol: Composition, Origin, and Available Forms

The efficacy of Buttercup is centered on the active component, Hexylresorcinol, which is a highly characterized synthetic organic compound derived from the phenol chemical group. This synthetic origin guarantees a consistent level of purity for the active agent, which is integrated into an ingestible base for the most common dosage form: the oromucosal lozenge. This format is specifically designed for the oromucosal route of administration, which facilitates sustained contact with the irritated tissues, a feature often differentiating it from quick-acting throat sprays. Buttercup is typically formulated as a single-active-ingredient product, often marketed toward the relief of sore throat pain.

What is the General Purpose of Buttercup?

The overall purpose of the medicine is to provide immediate, symptomatic comfort by temporarily reducing the sensation of minor pain and soreness in the mouth and throat. This application relies on the compound's capacity to induce a localized numbing effect. Hexylresorcinol has recognized roles as both an oral pain reliever and a first aid antiseptic. This relief is achieved through the compound's ability to act as a local anesthetic on the peripheral nerve endings, combined with its mild antiseptic activity which helps reduce the microbial presence on the tissue surface.

What side effects are possible with Buttercup?

Possible Side Effects and Safety Information

The officially documented safety profile of Hexylresorcinol lozenges (Buttercup) primarily involves effects at the site of application and the potential for allergic reactions, as defined in regulatory documents.

Documented Adverse Reactions

The most commonly expected adverse reactions are localized, temporary effects related to the mouth and throat (Administration Site Conditions):

System-Organ Class Example Reaction
General Disorders Local irritation or discomfort
Gastrointestinal Disorders Sore tongue

Adverse events related to the Immune System are also documented as potential side effects. The frequency of Hypersensitivity (allergic reactions), which may include rash or swelling, is often classified as Not Known in official product information, reflecting limitations in available data. Severe manifestations of hypersensitivity, such as angioedema (swelling of the face, throat, or tongue), are serious adverse reactions that are potentially associated with the drug's use.


Safety Considerations and Restrictions

Official regulatory labeling includes specific restrictions and constraints based on the product's formulation and dosage form:

  • Contraindications: Use is restricted in patients with a known allergy to Hexylresorcinol or any of the inactive ingredients.
  • Population Restrictions: The lozenge form is typically contraindicated for use in children under 6 years due to the risk of choking. Furthermore, due to the sugar content, the medicine is contraindicated for individuals with rare hereditary problems, such as fructose intolerance or glucose-galactose malabsorption.
  • Exposure Note: Excessive intake or over-dosage has been documented to potentially cause minor gastrointestinal irritation.

Overdose and Emergency Response

The official regulatory profile for Hexylresorcinol lozenge overdosage focuses on a limited range of expected manifestations and strictly mandated immediate emergency actions. The documented clinical presentation is classified as mild.

Overdose Scope Official Regulatory Statement
Documented Manifestations Minor gastrointestinal irritation is the specific clinical sign described in authoritative regulatory documents. Systemic or severe life-threatening outcomes are not documented as the expected direct pharmacological presentation for this type of overdosage.
Required Management The defined treatment approach is limited to the withdrawal of the product (discontinuation) and the implementation of non-specific symptomatic measures. No specific pharmacological antidote is listed in the supportive treatment sections of the authoritative prescribing information.

In all instances where overdosage is suspected, government labeling mandates an immediate emergency response. Individuals must get medical help or contact a Poison Control Center right away, a requirement that applies regardless of whether specific symptoms have yet manifested. This instruction establishes the critical safety trigger defined by regulatory authorities for over-ingestion. Regulatory documents do not contain specific statements detailing a toxic dose level, nor do they list altered severity risks for particular populations, such as pediatric, elderly, or renally impaired patients, in the context of overdosage. The overall profile confirms that professional medical consultation is required for any accidental or suspected excess intake.

Therapeutic Uses of Buttercup

What Buttercup Treats: Main Uses and Benefits

The primary therapeutic role of the Hexylresorcinol lozenge is relevant for easing discomfort and provides supportive relief for discomfort within the oropharyngeal area, focusing on conditions involving episodic or fluctuating manifestations that are minor and acute. The active ingredient functions as an oral pain reliever for symptomatic relief of the mouth and throat.

This medication is commonly used to help manage symptoms related to physical discomfort such as localized pain, aching, and scratchiness of the throat, as well as minor mucosal irritation. It is applied across domains where additional symptomatic support is needed, primarily for conditions presenting with acute episodes. The lozenge helps address symptom clusters that may become intense or disruptive, and is relevant for addressing secondary discomfort that often makes swallowing difficult during an acute episode.

“This supportive relief is considered relevant in contexts marked by increased discomfort and tension.”

The use of this medication for local discomfort contributes to improved comfort during periods of acute discomfort by easing the overall symptom load. The main symptomatic indications for this use include sore throat, mouth irritation, and symptom clusters associated with conditions like pharyngitis.

Symptom Management Summary
Symptom Focus Minor pain, soreness, and mucosal irritation.
Therapeutic Benefit Provides supportive relief, which may assist with maintaining comfort during swallowing.
Typical Context Relevant for short-term symptomatic assistance during acute episodes.

Regulatory References

  1. DailyMed — Hexylresorcinol Labeling

Eligibility and Restrictions for Use

Who can and cannot use Buttercup?

Regulatory agencies define the eligibility for Hexylresorcinol lozenges based on age, hypersensitivity, and specific pre-existing health conditions related to the product’s components. Use is permitted for adults, the elderly, and children 6 years of age and over.

Contraindications: Who Must Not Use

Use of this medicine is an absolute contraindication in the following populations:

  • Children under 6 years of age: Safety and effectiveness have not been established in this age group, and the lozenge form poses a documented choking risk.
  • Patients with known hypersensitivity (allergy) to Hexylresorcinol or any non-active ingredients.
  • Individuals with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency (due to the presence of glucose and sucrose).

Conditional Use and Restrictions

Population Group Eligibility Status (Regulatory Labeling)
Pregnancy Use with caution; there is a lack of sufficient human data. Conditional use requires assessment.
Lactation/Breastfeeding Use with caution; it is unknown if the substance or its metabolites are excreted in human milk.
Diabetes Mellitus Permitted, but the sugar content must be taken into account by the patient.

Eligibility is also restricted for patients with documented allergies to excipients such as certain azo dyes (e.g., Carmoisine E122) or Sulphites, which may be present in the lozenge formulation.

What should I know about interactions with other medicines?

Buttercup Interactions with other medicines and products (Hexylresorcinol)

The official interaction profile for Hexylresorcinol lozenges is derived strictly from government regulatory documentation, such as the Summary of Product Characteristics (SmPC). This profile is characterized by the absence of documented interactions with other medicinal products.

Documented Interaction Patterns

The regulatory labeling for single-active-ingredient Hexylresorcinol lozenges explicitly states that no known interactions with other medicines have been established. This finding reflects the drug’s highly localized action.

Interaction Type Official Regulatory Status
Drug-Drug Interactions None documented.
Metabolic (CYP) / Transporter None documented. Minimal systemic exposure noted, negating the basis for these interactions.
Pharmacodynamic None documented.

Restrictions and Other Contexts

Due to its local effect, the official interaction profile contains no specific restrictions typically associated with systemic drug interactions. The practical implications are:

  • Contraindicated Combinations: None are formally classified as prohibited due to an interaction risk with Hexylresorcinol alone.
  • Timing Separation: No mandatory timing separation rules for co-administering other products are listed in the official labeling.
  • Food/Alcohol/Supplements: No explicit warnings or restrictions regarding food, alcohol, or herbal products are documented.

Mechanism of Action

Buttercup's primary mechanism involves the hydrolysis of the inactive glycoside ranunculin into the volatile aglycone protoanemonin and glucose. This chemical transformation is catalyzed by glycosidase enzymes following plant cell or tissue damage. Protoanemonin, the biologically active molecular species, acts as an acylating agent that forms adducts with exposed biological nucleophiles, particularly sulfhydryl groups (thiols) on target proteins. This interaction results in the covalent modification and subsequent inactivation of numerous proteins and enzymes within contacted cellular structures, leading to widespread cytotoxicity. At the systemic level, this non-selective protein alkylation primarily targets tissues with direct exposure, such as epithelial cells of the dermis and mucous membranes. This local cellular damage triggers inflammatory cascades, resulting in the release of various algogenic and vasoactive mediators and local vasodilation, which modulates tissue perfusion and cellular ingress.

Dosage and Administration Information

How to Use Buttercup: Official Administration Guidelines

The usage of Hexylresorcinol lozenges for minor throat and mouth irritation is defined by specific administration guidelines to ensure proper local action.


Administration Scope

The approved route of administration is oromucosal, meaning the medicine is applied locally to the mucous membrane of the mouth and throat. This requires the lozenge to be allowed to dissolve slowly in the mouth; it must not be chewed or swallowed whole.

Category Official Instruction Summary
Standard Dosing (Adults & Age 12+) One lozenge per dose is standard, with some labels permitting two lozenges consecutively for certain strengths.
Maximum Daily Dose The maximum intake is restricted to between 10 and 12 lozenges in a 24-hour period, depending on the specific product formulation.
Dosing Frequency Doses may be repeated every 2 hours or every 3 hours as needed for symptoms, ensuring the minimum interval is observed and the maximum daily limit is not exceeded.

Population-Specific and Duration Rules

The regimen for children 12 years of age and older is typically the same as the adult dose. For children 6 to under 12 years of age, official guidance may specify a distinct regimen, such as a lower maximum dose or different frequency. Use in children under 6 years is generally not recommended.

This medication is intended for short-term use only. Official instructions advise against using the lozenges for an extended period, typically no more than 7 consecutive days, as the use protocol is designed for temporary symptomatic relief.

Recent Clinical Evidence

Research evidence / Overview of studies for Buttercup


Evidence for Use in Symptomatic Relief of Acute Sore Throat

The research on Hexylresorcinol lozenges primarily consists of short-term randomized controlled trials (RCTs). These are studies used in research exploring how symptoms change over time by comparing the lozenge to an inactive placebo in volunteer populations. Researchers focused on study endpoints related to physical discomfort, such as measuring changes in the intensity of throat soreness and the difficulty swallowing (dysphagia) that is often associated with acute episodes. The studies mainly included adults and adolescents (typically aged 12 years and older) experiencing a recent onset of throat discomfort.

Research has explored how symptoms evolved in the observed populations during the study period. Findings describe patterns observed in the studies related to localized sensory changes and temporary changes in symptom scores. However, certainty is low regarding the full range of potential long-term outcomes. Follow-up durations were limited, focusing mostly on the immediate period after use.


Studies on the Antiseptic Activity

The medicine's active ingredient was evaluated for its classification as a topical anti-infective. This aspect was evaluated in pre-clinical in vitro (laboratory) assays rather than human clinical trials. These studies examined the lozenge's activity against certain bacteria and viruses that may be associated with acute episodes of throat discomfort. Laboratory assays described patterns of antimicrobial activity when Hexylresorcinol was tested in these controlled culture settings.

These laboratory results provide context for the compound's dual classification. However, the complex biological environment of the human throat is not fully established by these artificial models. Therefore, the findings from these in vitro studies cannot be directly translated to a proven clinical outcome in a patient's body.


What is Still Uncertain in the Research Landscape

Research highlights what is known—and what is still uncertain—about this medicine. A key area of uncertainty relates to the overall certainty of the evidence, as the effect size data were limited or mixed in some studies. Furthermore, the clinical link between this activity and changes in patient-reported outcomes is not fully established. Data for certain groups, such as younger children, remain insufficient. The available evidence contributes to understanding symptom patterns only within the narrow, short-term research scenarios under which they were conducted.

Key Studies & References

  1. Sore throat (acute): antimicrobial prescribing - Summary of the evidence (Guidance NG84)
  2. Hexylresorcinol (DailyMed Monograph/Labeling)

Frequently Asked Questions (FAQ)

Common questions about Buttercup (FAQ)

Q: Can Buttercup cause stomach upset or digestive issues?

A: According to official regulatory documents, overdosage of Hexylresorcinol lozenges may potentially cause minor gastrointestinal irritation. When used as directed, the most commonly expected adverse reactions are localized to the mouth and throat. If any digestive symptoms are persistent or unexpected, a healthcare professional should be consulted.


Q: Is an allergic reaction, like a rash, a possible side effect of Buttercup?

A: Regulatory product information documents list hypersensitivity (allergic) reactions as a possible side effect. These reactions may include a rash, urticaria (hives), and angioedema (swelling of the face, tongue, or throat). Official instructions advise that if signs of a severe allergic reaction occur, seeking immediate medical attention is necessary.


Q: Is it safe to take Buttercup if I have a sugar intolerance or diabetes?

A: Official information states that Hexylresorcinol lozenges typically contain glucose and sucrose, and this must be taken into account by individuals managing diabetes mellitus. Furthermore, the lozenges are contraindicated (must not be used) for patients who have rare hereditary problems such as fructose intolerance or glucose-galactose malabsorption.


Q: Does Buttercup address both the throat irritation and the urge to cough?

A: The active ingredient, Hexylresorcinol, is classified as a local anesthetic and mild antiseptic, which helps relieve pain and minor irritation in the throat. The lozenge base also provides a demulcent action, which is a soothing effect. The product's primary indication is the relief of sore throat and irritation; the regulatory text does not explicitly indicate relief for the urge to cough.


Q: Does Buttercup contain any sugar or alcohol that I should be aware of?

A: Yes, official product information confirms that the lozenge contains sugars, including glucose and sucrose, which is noted as relevant information for individuals managing diabetes. Alcohol is not listed as an excipient in the regulatory information for the lozenge formulation.


Q: Is there a safe Buttercup product for younger children or toddlers?

A: The lozenge form is contraindicated for use in children under 6 years of age. This restriction is primarily due to the established risk of choking, and because safety and effectiveness have not been established in this age group. Regulatory documents do not confirm the existence of alternative product forms for younger children.


Q: Does Buttercup contain ingredients that might make asthma symptoms worse?

A: Some lozenge formulations may contain Sulphur Dioxide (E220), which is an excipient (non-active ingredient). Official warnings state that Sulphur Dioxide may rarely cause severe hypersensitivity reactions and bronchospasm (a tightening of the airways) in susceptible individuals.


Q: Is it normal to feel a warming sensation in the throat after taking Buttercup?

A: The documented common adverse reaction for this product is localized irritation or discomfort at the site of application. Any sensation that is severe or persistent should be discussed with a healthcare professional.


Q: What are the non-active ingredients in the syrup, besides the main extracts?

A: Official product labeling lists the excipients, or non-active ingredients, that are added to the lozenge base. These vary by specific product but commonly include sugars such as liquid sucrose and liquid glucose, as well as specific flavorings and colorings.


Q: Does Buttercup help with cold symptoms other than just the cough?

A: The medicine is officially indicated for the temporary relief of sore throat and minor irritations of the mouth. While these symptoms can be associated with a cold, the product's regulatory indication does not extend to general cold symptoms such as congestion or runny nose.


Q: Is Buttercup effective for a sore throat that is scratchy or irritated?

A: Yes, the lozenge is officially indicated for the temporary relief of minor irritation and pain in the mouth and sore throat. This indication covers the common experience of a scratchy or irritated throat.


Q: How long does the soothing effect of Buttercup typically last?

A: Official dosing guidelines state that the lozenge dose is authorized to be repeated every 2 or 3 hours as needed. This repeat frequency indicates that the symptomatic relief provided by the product is temporary.


Q: What is the role of the caramel color and other additives in the syrup?

A: Additives such as colors and flavorings are listed as excipients in the product's official summary. Their role is non-medicinal, meaning they are used solely for the purpose of coloring and flavoring the product base.


Q: Is the ginger or aniseed flavor in Buttercup medicinal or just for taste?

A: Flavorings used in the product are classified as excipients in regulatory documents, which are non-active ingredients. They are added for taste purposes and are not considered to contribute to the primary therapeutic (medicinal) effect of the lozenge.


Q: What are the signs that I should stop taking Buttercup and contact a doctor?

A: Official warnings state that use should be stopped if the sore throat is severe, persists for more than 2 days, or is accompanied or followed by signs such as fever, headache, rash, swelling, nausea, or vomiting.


Q: Can I experience dizziness as a side effect from Buttercup?

A: Dizziness is not listed as a documented adverse reaction in the official EU Summary of Product Characteristics (SmPC) for Hexylresorcinol lozenges. The most common side effects are localized to the mouth and throat.


Q: Why do some Buttercup products contain a warning about driving or operating machinery?

A: Regulatory information for the Hexylresorcinol lozenge specifically states that the product has no or negligible influence on the ability to drive and use machines.

How should Buttercup be stored and disposed of?

How to Store and Dispose of Hexylresorcinol Lozenges

The storage and disposal of this medicine must strictly follow the conditions detailed in official regulatory labeling to ensure product integrity and safety.

Storage Requirements

The product must be kept below the maximum temperature specified on the carton, which is typically 25 C or 30 C. To maintain product integrity, the lozenges must be stored in the original packaging. It is prohibited to use the medicine after the expiry date printed on the carton.

Safety and Disposal

For child safety, the medicine must be kept out of the sight and reach of children at all times. Regulatory instructions prohibit throwing away unused or expired medicine via wastewater or household waste as a measure to protect the environment. Instead, users are directed to ask a pharmacist for guidance on proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Buttercup found in:

A-Z Index: